Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arie Regev

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Biomarkers in Medicine|December 2, 2025
Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studiesRavindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2023
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver ForumMelissa Palmer, David E Kleiner, Zachary Goodman, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 15, 2005
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantationPanagiotis Tryphonopoulos, Andreas G Tzakis, Debbie Weppler, et al.
Drug Safety|November 3, 2020
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic SteatohepatitisWilliam R Treem, Melissa Palmer, Isabelle Lonjon-Domanec, et al.
Chemical Research in Toxicology|October 13, 2025
Industry Perspective on Nonclinical Approaches for Hepatotoxicity Risk Assessment: Insights from Two Longitudinal Surveys Conducted in 2023 and 2017Melanie Z Sakatis, Leah M Norona, Jamie E Karmel, et al.
Journal of Clinical and Translational Hepatology|May 9, 2022
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory ScienceYasser Fouad, Melissa Palmer, Minjun Chen, et al.
Journal of Autoimmunity|August 10, 2020
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug developmentArie Regev, Mark I Avigan, Alexandre Kiazand, et al.
Journal of Hepatology|May 10, 2023
Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting reportRaúl J Andrade, Guruprasad P Aithal, Ynto S de Boer, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Biomarkers in Medicine|December 2, 2025
Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studiesRavindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2023
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver ForumMelissa Palmer, David E Kleiner, Zachary Goodman, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 15, 2005
The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantationPanagiotis Tryphonopoulos, Andreas G Tzakis, Debbie Weppler, et al.
Drug Safety|November 3, 2020
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic SteatohepatitisWilliam R Treem, Melissa Palmer, Isabelle Lonjon-Domanec, et al.
Chemical Research in Toxicology|October 13, 2025
Industry Perspective on Nonclinical Approaches for Hepatotoxicity Risk Assessment: Insights from Two Longitudinal Surveys Conducted in 2023 and 2017Melanie Z Sakatis, Leah M Norona, Jamie E Karmel, et al.
Journal of Clinical and Translational Hepatology|May 9, 2022
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory ScienceYasser Fouad, Melissa Palmer, Minjun Chen, et al.
Journal of Autoimmunity|August 10, 2020
Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug developmentArie Regev, Mark I Avigan, Alexandre Kiazand, et al.
Journal of Hepatology|May 10, 2023
Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting reportRaúl J Andrade, Guruprasad P Aithal, Ynto S de Boer, et al.
Pageof 7